Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
BERKELEY, Calif., March 14, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market opens on Thursday, March 16, 2017. In conjunction, the Company will host a conference call at 9:00 a.m. ET on Thursday, March 16, 2017, to review its business highlights and describe XOMA’s new strategic direction and initiatives.
The webcast can be accessed via the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay. An accompanying slide presentation also can be accessed via the XOMA website. Telephone numbers for the live conference call are 1-877-369-6589 (U.S./Canada) and 1-408-337-0122 (international) with the passcode 82058103.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
